Anne W. Beaven, MD
Department / Division
Medicine /
Medicine - Hematological Malignancies
Address
DUMC 3872
Durham, NC 27710
Appointment Telephone
919-684-8964
Office Telephone
919-684-8964
Fax Telephone
919-684-5325
- MD, University of North Carolina–Chapel Hill School of Medicine, 2000
- Internal Medicine, UNC Hospitals, 2000-2003
- Hematology-Oncology, UNC Hospitals, 2004-2007
Clinical Interests
Treatment of hematologic malignancies, clinical trials in lymphoma
Research Interests
My particular area of research interest is clinical trails for patients with lymphoma.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- GlaxoSmithKline
Representative Publications
Beaven, AW; Shea, TC; Moore, DT; Feldman, T; Ivanova, A; Ferraro, M; Ford, P; Smith, J; Goy, A. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma. 2012;53:254-258.
(2012)
Abstract
Beaven, AW; Moore, DT; Sharf, A; Serody, JS; Shea, TC; Gabriel, DA. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Cancer Investigation. 2011;29:214-219.
(2011)
Abstract
Dorth, JA; Chino, JP; Prosnitz, LR; Diehl, LF; Beaven, AW; Coleman, RE; Kelsey, CR. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Annals of Oncology. 2011;22:405-410.
(2011)
Abstract
Kelsey, CR; Beaven, AW; Diehl, LF; Prosnitz, LR. Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?. Oncology. 2010;24:1204-1212.
(2010)
Abstract
Shea, TC; Beaven, AW; Moore, DT; Serody, JS; Gabriel, DA; Chao, N; Gockerman, JP; Garcia, RA; Rizzieri, DA. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia and Lymphoma. 2009;50:741-748.
(2009)
Abstract
